✦ LIBER ✦

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

✍ Scribed by van Etten, Richard A.; Mauro, Michael; Radich, Jerald P.; Goldman, John M.; Saglio, Giuseppe; Jamieson, Catriona; Soverini, Simona; Gambacorti-Passerini, Carlo; Hehlmann, Rüdiger; Martinelli, Giovanni; Perrotti, Danilo; Scadden, David T.; Skorski, Tomasz; Tefferi, Ayalew; Mughal, Tariq I.

Book ID: 120571195
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 230 KB
Volume: 54
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2012.745524

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chronic myeloid leukemia 2011: Successes

Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

✍ Tariq I. Mughal; Jerald P. Radich; Richard A. Van Etten; Alfonso Quintás-Cardama 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Unraveling the genetic underpinnings of

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium

✍ Omar Abdel-Wahab; Animesh Pardanani; Olivier A. Bernard; Guido Finazzi; John D. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

NCI First International Workshop on the

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms, and Lymphoid Malignancies

✍ Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J. Boro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 305 KB

Imatinib dose escalation in two patients

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Martina Divoká; Beata Katrincsáko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB